Chong Kun Dang Obtains MFDS Approval for Type 2 Diabetes Combination Drug Empamax S

Jongkundang announced on the 8th that it has obtained product approval from the Ministry of Food and Drug Safety for Empamax S tablets (active ingredients empagliflozin, sitagliptin) in 25/100 mg and 10/100 mg dosages.

With the product approval, Jongkundang expects to provide a new treatment option for patients with type 2 diabetes whose blood sugar is not adequately controlled by combination therapy of empagliflozin and sitagliptin, and to improve medication convenience.

Jongkundang applied for product approval of Empamax S tablets to the Ministry of Food and Drug Safety on May 14 last year and plans to launch it in the domestic market in November.

This content was produced with the assistance of AI translation services.